{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:38Z","timestamp":1793506598251,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,2,4]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Programmed death 1 (PD-1) inhibitor demonstrated durable antitumor activity in advanced esophageal squamous cell carcinoma (ESCC), but the clinical benefit of perioperative immunotherapy in ESCC remains unclear. This study evaluated the efficacy and safety of neoadjuvant chemoradiotherapy (nCRT) combined with the PD-1 inhibitor toripalimab in patients with resectable ESCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From July 2020 to July 2022, 21 patients with histopathologically confirmed thoracic ESCC and clinical staged as cT1-4aN1-2M0\/cT3-4aN0M0 were enrolled. Eligible patients received radiotherapy (23 fractions of 1.8 Gy, 5 fractions a week) with concurrent chemotherapy of paclitaxel\/cisplatin (paclitaxel 45 mg\/m<jats:sup>2<\/jats:sup> and cisplatin 25 mg\/m<jats:sup>2<\/jats:sup>) on days 1, 8, 15, 22, 29 and two cycles of toripalimab 240\u2009mg every 3 weeks after nCRT for neoadjuvant therapy before surgery, four cycles of toripalimab 240\u2009mg every 3 weeks for adjuvant therapy after surgery. The primary endpoint was the major pathological response (MPR) rate. The secondary endpoints were safety and survival outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 21 patients were included, of whom 20 patients underwent surgery, 1 patient refused surgery and another patient was confirmed adenocarcinoma after surgery. The MPR and pathological complete response (pCR) rates were 78.9% (15\/19) and 47.4% (9\/19) for surgery ESCC patients. 21 patients (100.0%) had any-grade treatment-related adverse events, with the most common being lymphopenia (100.0%), leukopenia (85.7%), neutropenia (52.4%). 14 patients (66.7%) had adverse events of grade 3 with the most common being lymphopenia (66.7%). The maximum standardized uptake value and total lesion glycolysis of positron emission tomography\/CT after neoadjuvant therapy well predicted the pathological response. The peripheral CD4+%, CD3+HLA-DR+\/CD3+%, CD8+HLA-DR+\/CD8+%, and IL-6 were significant differences between pCR and non-pCR groups at different times during neoadjuvant therapy. Three patients had tumor relapse and patients with MPR have longer disease-free survival than non-MPR patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>nCRT combined with perioperative toripalimab is effective and safe for locally advanced resectable ESCC. Long-term survival outcomes remain to be determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04437212\">NCT04437212<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-008631","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:00:10Z","timestamp":1709863210000},"page":"e008631","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04437212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03490292","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6392-804X","authenticated-orcid":false,"given":"Xin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rui","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2025100510371258000_12.3.e008631.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025100510371258000_12.3.e008631.2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108"},{"key":"2025100510371258000_12.3.e008631.3","first-page":"21","article-title":"Patterns and trends in Esophageal cancer incidence and mortality in China: an analysis based on cancer registry data","volume":"3","author":"Chen","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2025100510371258000_12.3.e008631.4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03614"},{"key":"2025100510371258000_12.3.e008631.5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced Esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"2025100510371258000_12.3.e008631.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007"},{"key":"2025100510371258000_12.3.e008631.7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100510371258000_12.3.e008631.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4443"},{"key":"2025100510371258000_12.3.e008631.9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced Esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"2025100510371258000_12.3.e008631.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced Esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100510371258000_12.3.e008631.11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable Esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100510371258000_12.3.e008631.12","doi-asserted-by":"crossref","first-page":"1031171","DOI":"10.3389\/fimmu.2022.1031171","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with resectable Esophageal squamous cell carcinoma: a prospective, single-arm, phase 2 trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2025100510371258000_12.3.e008631.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"2025100510371258000_12.3.e008631.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088"},{"key":"2025100510371258000_12.3.e008631.15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100510371258000_12.3.e008631.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039020","article-title":"Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in Esophageal cancer: a meta-analysis and systematic review","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100510371258000_12.3.e008631.17","doi-asserted-by":"crossref","first-page":"102118","DOI":"10.1016\/j.eclinm.2023.102118","article-title":"A phase II clinical trial of Toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced Esophageal squamous cell carcinoma","volume":"62","author":"Chen","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2025100510371258000_12.3.e008631.18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025100510371258000_12.3.e008631.19","doi-asserted-by":"crossref","first-page":"1041126","DOI":"10.3389\/fimmu.2022.1041126","article-title":"The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"2025100510371258000_12.3.e008631.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483"},{"key":"2025100510371258000_12.3.e008631.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6532"},{"key":"2025100510371258000_12.3.e008631.22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive Esophagectomy for locally advanced Esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"key":"2025100510371258000_12.3.e008631.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable Esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100510371258000_12.3.e008631.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1170569","article-title":"Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable Esophageal cancer: a systematic review and single-arm and network meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2025100510371258000_12.3.e008631.25","doi-asserted-by":"crossref","unstructured":"von D\u00f6beln GA , Klevebro F , Jacobsen A-B , et al . Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis Esophagus 2019;32. doi:10.1093\/dote\/doy078","DOI":"10.1093\/dote\/doy078"},{"key":"2025100510371258000_12.3.e008631.26","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1200\/JCO.22.02279","article-title":"Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in Esophageal or gastroesophageal junction carcinoma","volume":"41","author":"Faron","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100510371258000_12.3.e008631.27","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1200\/JCO.2019.37.15_suppl.4041","article-title":"Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable Esophageal and gastroesophageal junction (E\/GEJ) cancer","volume":"37","author":"Uboha","year":"2019","journal-title":"JCO"},{"key":"2025100510371258000_12.3.e008631.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100385","article-title":"Adjuvant durvalumab for Esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study","volume":"7","author":"Park","year":"2022","journal-title":"ESMO Open"},{"key":"2025100510371258000_12.3.e008631.29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"The Lancet"},{"key":"2025100510371258000_12.3.e008631.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380"},{"key":"2025100510371258000_12.3.e008631.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"2025100510371258000_12.3.e008631.32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025100510371258000_12.3.e008631.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-022-01252-6","article-title":"Association of the tissue infiltrated and peripheral blood immune cell subsets with response to radiotherapy for rectal cancer","volume":"15","author":"Zhu","year":"2022","journal-title":"BMC Med Genomics"},{"key":"2025100510371258000_12.3.e008631.34","doi-asserted-by":"crossref","unstructured":"Du X , Wen S , Shi R , et al . Peripheral blood lymphocytes differentiation patterns in responses\/outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. BMC Cancer 2023;23. doi:10.1186\/s12885-023-10502-4","DOI":"10.1186\/s12885-023-10502-4"},{"key":"2025100510371258000_12.3.e008631.35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148692","article-title":"The current understanding of the immune landscape relative to radiotherapy across tumor types","volume":"14","author":"Iliadi","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:37:21Z","timestamp":1759685841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/jitc-2023-008631"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008631","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}